February 2006 in “PubMed” Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
2 citations
,
February 2014 in “Journal of Crohn's and colitis” Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
1 citations
,
August 2024 in “Skin Health and Disease” Topical immunotherapy with DPCP led to some hair regrowth in most pediatric alopecia areata patients, especially those with milder cases and longer treatment.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
8 citations
,
June 2021 in “Frontiers in Medicine” The combination of the excimer lamp and liquor carbonis detergens is more effective for scalp psoriasis than the lamp alone.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
August 2024 in “New Zealand Medical Student Journal” JAK inhibitors show promise for treating skin diseases effectively and safely.
39 citations
,
November 2015 in “Pediatric Nephrology” Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
25 citations
,
August 2011 in “The Journal of Allergy and Clinical Immunology” Finasteride caused a rare skin rash in a man, which improved after stopping the medication.
1 citations
,
April 2013 in “PubMed” August 2024 in “JAAD Case Reports” Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
December 2020 in “Dermatología argentina” A patient got a skin reaction on their hands and feet after using secukinumab for psoriasis.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2025 in “Biomedical Reports” Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
10 citations
,
June 2016 in “PLOS ONE” Finasteride boosts immune cells that suppress T-cells, possibly helping with immune disorders but may increase cancer risk.
16 citations
,
August 2011 in “Annals of Allergy Asthma & Immunology” A woman with severe angioedema improved significantly after treatment with rituximab.
4 citations
,
November 2020 in “Acta Dermato Venereologica” Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.
1 citations
,
April 2025 in “Skin Health and Disease” Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
15 citations
,
April 2011 in “Pediatric Nephrology” New treatments for lupus show promise, but more research is needed, especially for children.
5 citations
,
November 2013 in “Case reports in dermatology” A woman's skin darkened after using dutasteride and pimecrolimus for hair loss, but improved when she stopped the medications and protected her skin from light.